Biotech Values

[exwannabe]

SGEN:

... isn't that about the "ballpark" for many of the newer approved therapies? Revlaimid, Provenge......and many others.

Agreed that it is the ballpark, but it does look to be pricier than the others (though I don't now what the mean number of cycles for Rev would be).

Given the effectiveness though, I would not expect to see a Provenge like push-back.